After hitting Indian IT majors with the H-1B visa fee hike, US President Donald Trump has now lobbed a pharma grenade by imposing 100% tariffs on branded and patented drugs starting October 1. While most Indian pharmaceutical companies primarily earn from generics, the move rattled investor sentiment, pulling down shares of Sun Pharma, Cipla, and Dr. Reddy's by up to 5%.